Literature DB >> 26959197

Current Therapies for the Medical Management of Diabetes.

Silvio E Inzucchi1, Sachin K Majumdar.   

Abstract

Diabetes affects a large and diverse number of individuals who share in common its risks for complications but who differ greatly from one another in age, health, and a number of circumstances influential to successful treatment. Because type 2 diabetes comprises the majority of diabetes cases, a number of agents have been developed for its treatment. Their unique properties offer opportunities to overcome some of the treatment limitations of older medicines and enable a more individualized and flexible approach to glucose-lowering. At the same time, new medications are accompanied by greater costs and uncertainties about their long-term benefits or safety, and thus the present state of care for type 2 diabetes places focus on a process of shared decision-making between the clinician and patient as to which treatments can optimize health while minimizing harms. We review the major classes of diabetes agents and provide some guidance for how one might approach decision-making in choosing among them.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26959197     DOI: 10.1097/AOG.0000000000001332

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  7 in total

Review 1.  Nanoformulations of flavonoids for diabetes and microvascular diabetic complications.

Authors:  Kopal Agarawal; Yogesh Anant Kulkarni; Sarika Wairkar
Journal:  Drug Deliv Transl Res       Date:  2022-05-30       Impact factor: 4.617

Review 2.  Activation of Nrf2 signaling by natural products-can it alleviate diabetes?

Authors:  Manuel Matzinger; Katrin Fischhuber; Elke H Heiss
Journal:  Biotechnol Adv       Date:  2017-12-28       Impact factor: 14.227

3.  Association of Genomic Instability with HbA1c levels and Medication in Diabetic Patients.

Authors:  Annemarie Grindel; Helmut Brath; Armen Nersesyan; Siegfried Knasmueller; Karl-Heinz Wagner
Journal:  Sci Rep       Date:  2017-02-02       Impact factor: 4.379

4.  TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models.

Authors:  Yoshinori Tsumura; Yu Tsushima; Azusa Tamura; Makiko Hasebe; Masanobu Kanou; Hirotsugu Kato; Tsunefumi Kobayashi
Journal:  PLoS One       Date:  2017-02-16       Impact factor: 3.240

5.  Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study.

Authors:  Elina Urpilainen; Mikko Marttila; Ari Hautakoski; Martti Arffman; Reijo Sund; Pirjo Ilanne-Parikka; Reetta Arima; Jenni Kangaskokko; Ulla Puistola; Marianne Hinkula; Esa Läärä
Journal:  BMC Cancer       Date:  2018-07-28       Impact factor: 4.430

Review 6.  Effects of Periodic Intensive Insulin Therapy: An Updated Review.

Authors:  Shu Dong; Hien Lau; Cody Chavarria; Michael Alexander; Allison Cimler; John P Elliott; Sandra Escovar; Jack Lewin; James Novak; Jonathan R T Lakey
Journal:  Curr Ther Res Clin Exp       Date:  2019-04-30

7.  p53 Rather Than β-Catenin Mediated the Combined Hypoglycemic Effect of Cinnamomum cassia (L.) and Zingiber officinale Roscoe in the Streptozotocin-Induced Diabetic Model.

Authors:  Nasra Ayuob; Mona Ramadan Al-Shathly; Abdulaziz Bakhshwin; Nouf Saeed Al-Abbas; Nehad A Shaer; Soad Al Jaouni; Walaa H E Hamed
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.